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Abstract: Choline kinase α1 (ChoKα1) has become an excellent antitumor target. Among all the
inhibitors synthetized, the new compound Ff35 shows an excellent capacity to inhibit ChoKα1 activity.
However, soluble Ff35 is also capable of inhibiting choline uptake, making the inhibitor not selective
for ChoKα1. In this study, we designed a new protocol with the aim of disentangling whether the
Ff35 biological action is due to the inhibition of the enzyme and/or to the choline uptake. Moreover,
we offer an alternative to avoid the inhibition of choline uptake caused by Ff35, since the coupling
of Ff35 to novel biomimetic magnetic nanoparticles (BMNPs) allows it to enter the cell through
endocytosis without interacting with the choline transporter. This opens the possibility of a clinical
use of Ff35. Our results indicate that Ff35-BMNPs nanoassemblies increase the selectivity of Ff35 and
have an antiproliferative effect. Also, we demonstrate the effectiveness of the tandem Ff35-BMNPs
and hyperthermia.
Keywords: biomimetic; magnetic nanoparticle; ChoKα1 inhibitor; Ff35; drug delivery; hyperthermia
1. Introduction
Chemoresistance to cancer is a major concern [1,2] that has prompted the development of new
effective therapies. Among then, those that affect lipid metabolism, whose alteration occurs in many
types of cancer [3,4], have gained great attention. Particularly, the metabolism of choline has been
associated with tumor onset and progression. In this context, choline kinase α 1 (ChoKα1) isoform has
been considered as biomarker of tumor progression and carcinogenesis [5–7], and it has emerged as
one of the most promising therapeutic target enzymes in cancer. ChoK catalyzes the phosphorylation
of choline to generate phosphocholine which, through cytidine 5´-diphosphocholine (CDP-choline) [8],
produces phosphatidylcholine. ChoKα also regulates the mitogen-activated protein kinase (MAPK)
and phosphoinositide 3-kinase (PI3K/AKT) signaling pathways [9]. Extensive efforts have been made
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to synthesize and improve ChoKα1 inhibitors in order to use them as chemotherapeutic agents [10,11],
since it is well known that ChoKα1 inhibitors have antiproliferative effect on several tumor cell
lines [12]. Hemicolinium-3 was the first one used in clinics, but it has multiple side effects, mainly due
to the inhibition of choline uptake and the impediment of the synthesis of acetylcholine [13]. Afterward,
bis-pyridinium and bis-quinolinium derivatives, namely MN58b and RSM-932A, respectively, were
also produced with high capacity to inhibit ChoKα1 activity and cell proliferation [14], and, even more
recently, several other compounds have been synthesized based on the chemical structure of the former
compounds [12]. In particular one of them, here referred as Ff35 (Figure 1), contains bioisoteric rings of
the quinoline, where carbon atoms have been replaced by nitrogen and sulphur atoms, and the same
spacer as that of the compound MN58b [15]. These changes would lead, on one hand, to an increase of
the polarity (and solubility) of the compound and, on the other hand, to an increase of the specificity
of the drug. The latter is due to the increasing number of free electron pairs that these modifications
induce, which can form hydrogen bonds or dipole–dipole type junctions between the molecule and
the enzyme, thus increasing the antiproliferative effect of the drug.
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Figure 1. Chemical structure of choline kinase α 1 (ChoKα1) inhibitor Ff35. 
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whether the resulting inhibition of tumor cell proliferation is due to the inhibition of the enzyme 
(which would allow the potential use of the compound in clinics) or whether it is caused by the 
inhibition of the choline uptake (which may prevent its potential use). Moreover, if the latter is the 
case, it is also crucial to design strategies to avoid the inhibition of choline uptake. A possibility to 
prevent such inhibition is to use carriers to introduce the specific ChoKα1 inhibitor in the cell without 
interacting with the choline transporters. In this context, one alternative is to couple the compound 
with nanoparticles that could enter the cell by endocytosis, as we propose for the first time in the 
present study. 
Among the potential nanocarriers, magnetic nanoparticles are preferred because of their 
biocompatibility and their magnetic properties, which, on one hand, allow their guidance to the target 
site and their concentration therein by the application of external magnetic fields and, on the other, 
they allow the nanoparticle itself to be used as hyperthermia agent [17]. Biomimetic magnetic 
nanoparticles, BMNPs, mediated by Magnetococcus marinus MC-1 magnetosome membrane protein 
MamC, have demonstrated themselves to be promising nanocarriers, able to couple with drugs 
forming stable nanoassemblies at physiological pH, while efficiently releasing the drug in acidic 
(tumor) environments in response to pH changes. In fact, these BMNPs present novel features 
compared to other nanoparticles produced inorganically and/or other biomimetic nanoparticles [18]: 
(1) They are superparamagnetic (single magnetic domain) at room and body temperature, behaving 
as nonmagnetic in the absence of an external magnetic field (thus minimizing aggregation), while 
they present a large magnetic moment per particle under the influence of an external magnetic field, 
thus optimizing their guidance and concentration at the target site. Such behavior is due to the fact 
that these BMNPs are larger than most commercial and/or other biomimetic magnetic nanoparticles. 
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However, it has been described that certain inhibitors of ChoKα1, besides hemicholinium-3, are
also capable of inhibiting choline uptake, thus making it more difficult, if not impossible, for their use in
systemic clinical treatments [16]. For this reason, firstly, for any newly synthesized inhibitor of ChoKα1
and before proposing it as antitumoral drug, it is imperative to design protocols to discern whether the
resulting inhibition of tumor cell proliferation is due to the inhibition of the enzyme (which would
allow the potential use of the compound in clinics) or whether it is caused by the inhibition of the
choline uptake (which may prevent its potential use). Moreover, if the latter is the case, it is also crucial
to design strategies to avoid the inhibition of choline uptake. A possibility to prevent such inhibition
is to use carriers to introduce the specific ChoKα1 inhibitor in the cell without interacting with the
choline transporters. In this context, one alternative is to couple the compound with nanoparticles that
could enter the cell by endocytosis, as we propose for the first time in the present study.
Among the potential nanocarriers, magnetic nanoparticles are preferred because of their
biocompatibility and their magnetic properties, which, on one hand, allow their guidance to the target
site and their concentration therein by the application of external magnetic fields and, on the other, they
allow the nanoparticle itself to be used as hyperthermia agent [17]. Biomimetic magnetic nanoparticles,
BMNPs, mediated by Magnetococcus marinus MC-1 magnetosome membrane protein MamC, have
demonstrated themselves to be promising nanocarriers, able to couple with drugs forming stable
nanoassemblies at physiological pH, while efficiently releasing the drug in acidic (tumor) environments
in response to pH changes. In fact, these BMNPs present novel features compared to other nanoparticles
produced inorganically and/or other biomimetic nanoparticles [18]: (1) They are superparamagnetic
(single magnetic domain) at room and body temperature, behaving as nonmagnetic in the absence of
an external magnetic field (thus minimizing aggregation), while they present a large magnetic moment
per particle under the influence of an external magnetic field, thus optimizing their guidance and
concentration at the target site. Such behavior is due to the fact that these BMNPs are larger than most
commercial and/or other biomimetic magnetic nanoparticles. (2) the BMNPs are cytocompatible and
even more, (3) they are produced by means of an eco-friendly, cost effective, easily scalable method.
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To our understanding, this is the first study that explores the functionalization of BMNPs with
a ChoKα1 inhibitor, such as Ff35, with the goal of obtaining a potential nanoassembly suitable for a
targeted chemotherapy that avoids possible side effects related to the inhibition of the choline uptake.
Moreover, the simultaneous use of hyperthermia is explored to optimize the effect of the targeted
chemotherapy in terms of increasing the cytotoxic effect of the nanoassembly. The in vitro antitumor
activity and the internalization of these complexes were investigated in the human hepatoblastoma
cell line, HepG2.
2. Materials and Methods
2.1. Expression and Purification of MamC. Synthesis and Characterization of the BMNPs by Transmission
Electron Microscop
MamC expression and purification was performed as previously described by Valverde-Tercedor
et al. [19]. Escherichia coli TOP10 (Invitrogen, Grand Island, NY, USA) were transformed with the
pTrcHis-TOPO plasmid (Invitrogen, Grand Island, NY, USA) carrying the MamC protein coding
gene (Mmc1_2265). These cells were grown at 37 ◦C and MamC overproduction was induced
with isopropyl-1-thio-β-d-galactopyranoside (IPTG). Afterwards, a HiTrap chelating HP column (Ge
Healthcare, Chicago, IL, USA) in an ÄKTA Prime Plus FPLC System (GE Healthcare, Chicago, IL,
USA) was used to purify the protein under denaturing conditions (6 M urea). Lastly, dialysis was
performed for a gradual removal of urea, which allowed MamC to refold progressively and the purity
was evaluated by SDS-PAGE electrophoresis.
BMNPs were synthesized from the following master solution: 10 µg mL−1 of the recombinant
MamC, Fe(ClO4)2 (2.78 mM), NaHCO3/Na2CO3 (3.5 mM/3.5 mM), FeCl3 (5.56 mM), pH 9, elaborated
from oxygen-free stock concentrated solutions of the individual compounds [20]. The master solution
was incubated for 30 days in an anaerobic COY chamber at 25 ◦C and 1 atm total pressure. After this
time, BMNPs were concentrated by using a magnet and the supernatant was discarded. Subsequently,
the precipitates were washed three times with Milly-Q deoxygenated water, suspended in HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffered saline solution (0.01 M HEPES, pH 7.2,
0.15 M NaCl), and sterilized at 121 ◦C for 21 min in an autoclave before their use.
The BMNPs used in the present study have been previously characterized in García-Rubia et
al. [18], and, therefore, only basic mineral characterization is included in the present manuscript.
According to these results, the BMNPs used in the present study are superparamagnetic magnetic
nanoparticles at 300 K, composed of ~95 wt% of magnetite and ~5 wt% of MamC, with an isoelectric
point of 4.4 and specific surface area of 90 m2/g.
For transmission electron microscopy (TEM) analyses of the BMNPs, a STEM Philips Model CM20
microscope was used. BMNPs were embedded into Embed 812 resin and then, ultrathin sections
(50–70 nm) were cut with a Reichert Ultracut S microtome (Leica Microsystems GmbH, Wetzlar,
Germany). ImageJ 1.47 software was used to measure particle sizes on multiple micrographs with over
1000 nanoparticles measured for each experiment to ensure reproducibility.
Hysteresis cycles and zero field cooling-field cooling (ZFC-FC) curves were carried out by using a
superconducting quantum interference device (SQUID) 5 T magnetometer (Quantum Design MPMS
XL, San Diego, CA, USA). Blocking temperature (TB) was calculated as the temperature at which the
maximum in magnetization occurred in ZFC curve.
2.2. Formation of Ff35-BMNPs Nanoassemblies
The kinetics of Ff35 adsorption on the magnetic nanoparticles was studied to determine the
time required for this adsorption to reach equilibrium. In these experiments, an aliquot of 5 mg of
BMNPs was mixed with 1 mL of Ff35 100 µM in HEPES buffer (10 mM HEPES, 150 mM NaCl, pH 7.2)
for several time intervals up to 48 h. After the incubation time, the Ff35-BMNPs nanoassemblies
(here referred as Ff35-BMNPs) were collected with a magnet and washed twice with HEPES buffer.
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Then, the supernatants were measured by UV-Vis spectroscopy at a wavelength of 304 nm and
these measurements were used to calculate the percentage of the absorbed compound. The molar
absorptivity of Ff35 in HEPES buffer at 304 nm was determined as 2677.5 L mol−1 (R2 = 0.9991)
from the slope of a standard calibration straight line. More than three replicas were performed per
experiment. The standard deviation of the absorbance measurements was used to calculate the error in
the concentration of Ff35 in the supernatant ([Ff35]sn).
The adsorption isotherm to calculate the saturation concentration of Ff35 adsorbed on the BMNPs
was determined by mixing an aliquot of 5 mg of BMNPs with 1 mL of several concentrations of Ff35
(ranging from 0 up to 200 µM) in HEPES buffer. These preparations were incubated at 25 ◦C under
continuous stirring for 6 h (time needed to reach equilibrium, according to the kinetics experiments).
Three replicas were performed per each measurement. After the incubation time, supernatants were
harvested, particles were washed, and UV-Vis spectroscopy measurements of all supernatants were
performed as described above. The data were fitted to the model of Langmuir-Freundlich (LF) by
using Origin 8. The LF model is based on Equation (1), where (Q) is the amount of adsorbed drug per
mass unit of adsorbent, (Ce) is the amount of nonadsorbed compound, (KLF) is the LF affinity constant,
and (r) is the cooperativity coefficient. A value of r < 1 means a negative cooperativity whereas a value







The human hepatoblastoma HepG2 cell line, used in this work, was acquired from the European
Collection of Animal Cell Cultures (Salisbury, UK). The cells were grown in Minimum Essential
Medium (MEM) containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 2 mM
l-glutamine, 1% nonessential amino acids, 100 U mL−1 penicillin, and 100 µg mL−1 streptomycin in a
humid atmosphere with 5% CO2 as 37 ◦C, and subcultured at a ratio of 1:10 once a week.
2.4. Inhibition of Choline Kinase α1 by Ff35
The effect of Ff35 on ChoK was assayed in purified ChoKα1 as previously described by Schiaffino et
al. [12], by determining the rate of incorporation of 14C from [methyl-14C]choline into phosphocholine,
both in the absence (control) or presence of different inhibitor concentrations. Briefly, the final reaction
mixture contained 100 mM Tris-HCl (pH 8.5), 10 mM MgCl2, 10 mM ATP, and 20 ng of purified
ChoKα1. The reaction was initiated with 1 mM [methyl-14C]choline (4500 dpm/nmol) and incubated
at 37 ◦C for 10 min. The assay was stopped by immersing the reaction tubes in boiling water for 3 min.
Aliquots of the reaction were applied to the origin of silica gel plates in the presence of phosphocholine
(0.1 mg) and choline (0.1 mg) as carriers. The chromatography was developed in methanol/0.6%
NaCl/28% NH4OH in water (50:50:5, v/v/v) as solvent, and phosphocholine was visualized under
exposure to iodine vapour. The corresponding spot was scraped and transferred to scintillation vials
for measurement of radioactivity by a Beckman 6000-TA (Madrid, Spain) liquid-scintillation counter.
The 50% inhibitory concentrations (IC50 value) were determined from the % activity of the enzyme at
different concentrations of synthetic inhibitor by using a sigmoidal dose-response curve (the ED50plus
v1.0 software).
2.5. Cell Proliferation Assay
HepG2 cells were seeded onto 96-well plates (10000 cells/well) and grown in MEM/10% FBS for
24 h. After 24 h, the medium was removed and 100µL of fresh medium containing Ff35 (1, 5, and 10µM),
BMNPs (300 µg mL−1), or Ff35-BMNPs (Ff35 1 µM and BMNPs 300 µg mL−1) were added for different
times. Cell viability was assayed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide). Formazan crystals were dissolved in 100 µL of DMSO, and the absorbance was read at a
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wavelength of 570 nm using a microplate reader (HTX Microplate Reader BioTek Instruments, Winooski,
VT, USA). The GI50 (half-maximal growth inhibitory concentration) value was determined from the
% cell viability at different concentrations of synthetic inhibitor by using a sigmoidal dose-response
curve (the ED50plus v1.0 software), referencing this value to an untreated cells control taken as a 100%
of the viability.
2.6. Inhibition of Choline Uptake by Ff35 and Ff35-BMNPs
Choline uptake was assayed as previously reported [22]. HepG2 cells were incubated for 10 min
at 37 ◦C in a MEM/10% FBS medium containing soluble Ff35 (0.5 and 1 µM), BMNPs (300 µg mL−1),
or Ff35-BMNPs (concentration of Ff35 was 0.5 µM and BMNPs was 150 µg mL−1 or that of Ff35
was 1 µM and BMNPs was 300 µg mL−1). After 10 min, 24 h, and 48 h of treatment, the cells were
immediately exposed to a pulse of [methyl-14C]choline (16 µM, 31 Ci/mol, in well) for 5 min at 37 ◦C.
The incorporation of choline was stopped by medium aspiration followed by two washes in ice-cold
PBS containing 580 µM choline. Then, the cells were solubilized in NaOH 0.1 N and an aliquot was
used to determine the total amount of radiolabeled choline taken up by the cells, measured by liquid
scintillation using a Beckman 6000-TA counter (Madrid, Spain).
2.7. Internalization of BMNPs or Ff535-BMNPs in the Cells
HepG2 cells were grown in six-well dishes for 24 h. Then, BMNPs (300 µg mL−1) or Ff35-BMNPs
(concentration of Ff35 was 1 µM and BMNPs was 300 µg mL−1) or only MEM/10% FBS medium, as
a control, were added for 24 h. Cells were collected using trypsin and centrifuged at 1500 rpm for
5 min in MEM/10% FBS. Cell pellets were fixed in 2.5% glutaraldehyde and 2% paraformaldehyde in
0.05 M cacodylate buffer for 4 h at 4 ◦C. The samples were washed three times with cacodylate buffer
and postfixed in an aqueous solution of 1% OsO4 containing 1% potassium ferrocyanide for 1 h at
4 ◦C in darkness. The following washes were done (25 ◦C): 0.15% tannic acid in cacodylate buffer,
cacodylate buffer, and H2O. The samples were left in 2% uranyl acetate for 2 h and washed several
times with H2O. Then, dehydration in ethanol solutions rising from 50% to 100% was done at 4 ◦C.
The samples were embedded in resin (EMbed 812/100% ethanol (1/1)) for 60 min at room temperature,
the same resin at a 2/1 ratio for 60 min, and then resin without ethanol overnight. For polymerization,
the samples were incubated in pure resin for 48 h at 60 ◦C. Ultrafine sections (50–70 nm) were cut using
a Leica Ultramicrotome R and contrasted using 1% aqueous uranyl acetate for 5 min and lead citrate in
a CO2-depleted atmosphere for 4 min [23]. A Zeiss Libra Plus 120 electron microscope was used to
visualize the sections.
2.8. Hyperthermia Analysis
Magnetic hyperthermia experiments were carried out using a laboratory-built AC current generator,
based on a Royer-type oscillator. The AC source was connected to a double five-turn coil built with
a copper tube 4 mm in diameter. This allowed control of the temperature of the coil by flowing
thermostated water. The coil was 20 mm in diameter and 45 mm long. The magnetic field frequency
was 197 ± 3 kHz, and its strength was H = 21 kA/m (B = 26.4 mT in air) at the center of the coil, where
the samples were placed, measured with a NanoScience Laboratories Ltd., Probe (Newcastle, UK), with
10 µT resolution. All samples were previously prethermostated at 37 ◦C. Prior to any determination,
the adiabatic condition of the system was verified by subjecting a sample of Milli-Q water as control,
in order to ensure that any temperature changes in the samples under study were due to the action
of the magnetic field, and not a consequence of environmental temperature gradient. A preliminary
experiment was performed with a suspension of bare BMNPs (300 µg mL−1) to set the conditions
(frequency and strength of the field and time of application) needed to guarantee that a temperature
of 43 ◦C was reached. The sample temperature was determined with an optical fiber thermometer
(Optocon AG, Dresden, Germany). For actual hyperthermia experiments, HepG2 cells were incubated
for 24 h at 37 ◦C with either 300 µg mL−1 BMNPs or Ff35-functionalized BMNPs and exposed to the
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AC magnetic field for time lapses ranging between 1 and 3 h. Immediately after the hyperthermia
treatment, the cells were processed for the MTT test.
2.9. Statistics
The results are shown as averages± SEM. A one-way ANOVA was done with post hoc comparisons
by Scheffé’s test (SPSS 13.0). p < 0.05 is considered statistically significant.
3. Results and Discussion
BMNPs exhibited well-developed faces and a size ranging from 20 to 50 nm, with an average
crystal size of 35 ± 8 nm, according to TEM analyses (Figure 2A,B). The hysteresis loop of BMNPs
showed a typical ferromagnetic behavior at 5 K, while at 300 K, these nanoparticles showed zero
coercivity, which indicates their superparamagnetic character, being that the magnetization saturation
(Ms) was at 300 K 55 emu/g (Figure 2C,D). The ZFC-FC curves at 500 Oe show a slow increase in
magnetization (Figure 2E). In fact, the TB was 150 K for BMNPs. According to Prozorov et al. [17], this
higher TB and slow magnetization increase is related to particles that expose a large magnetic moment
per particle and high crystallinity.
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The kinetics of Ff35 adsorption on BMNPs over time shows that the system reached equilibrium
at ~6 h (Figure 3A). The amount of adsorbed drug per amount of nanoparticles (Q) increased with the
equilibrium concentration of Ff35 in the supernatant (Ce) at a higher rate at the lowest Ce values. Such a
rate decreased as Ce increased (Figure 3B). The adsorption isotherm adjusts to the Langmuir-Freundlich
(LF) models (R2 = 0.93402), showing a drug loading capacity (Qmax) of 0.0026 ± 0.0003 mg Ff35 mg
magnetite−1. This model introduces the effects of energetic heterogeneity of the surface and the
cooperativity between Ff35 molecules, meaning that once a Ff35 molecule is coupled to BMNPs, it
lowers the energy required for the coupling of the next ones. The values of the LF affinity constant (KLF)
and cooperativity coefficient (r) parameters, calculated by means of this model were of 40 ± 10 mg of
Ff35 per mg of magnetite and 1.5 ± 0.6, respectively.
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the nonlineal weighted least-squares (N LS) fitting of the experi ental data according to F el.
In the case of adsorption kinetics, the vertical error bars are smaller than the symbol.
Our results show that BMNPs are able to carry 0.0026 mg of Ff35 per mg of magnetite (Qmax). Due
to the fact that this is the first study on Ff35 adsorption on magnetite nanoparticles (or on any other
nanoparticles), comparisons of the Qmax of the present study are done in reference to other studies
involving either the BMNPs used here or other nanocarriers. The Qmax value obtained in the present
manuscript was lower than those values obtained for the coupling of other drugs like doxorubicin
(DOXO) to BMNPs. For example, the adsorption of DOXO on the same BMNPs was 0.69 ± 0.03 mg
DOXO/mg BMNPs [18] or 0.41 ± 0.03 mg DOXO/mg apatite for DOXO adsorption on citrate-coated
apatite [24]. Even though Qmax for Ff35 is about two orders of magnitude lower than that for other
compounds, this amount that is coupled to the BMNPs is enough to have a cytotoxic effect as it will be
shown below.
The BMNPs’ loading capacity could be explained, on the one hand, by the electrostatic interaction
occurring at pH 7.2 (pH value at which the coupling occurs) between Ff35, which exposes two
basic groups, positively charged and the negatively charged magnetite surface (isoelectric point
(iep) = 4.4) [18], which allows Ff35 to be bound to the BMNPs, as previously demonstrated for
other nanoassemblies involving BMNPs and positively charged molecules [18]. However, when
the environmental pH decreases approaching the iep of the BMNPs (as it naturally does in a tumor
environment, for instance, in the endosome-lysosome compartment [25]), the electrostatic interactions
between Ff35 and BMNPs weaken, prompting Ff35 release. This characteristic presents a relevant point
for the potential clinical application of Ff35-BMNPs nanoassemblies, since no Ff35 release is expected
in the bloodstream until the nanoparticles reach the target tumoral (acidic) environment. On the other
hand, the results show that not only electrostatic interactions between the drug and the BMNPs would
be responsible for the Ff35-BMNPs nanoassemblies formation, since the r coefficient obtained in LF
model (r > 1) demonstrates a strong positive cooperativity between the molecules of Ff35 during the
adsorption process. This type of interaction has been previously described in DOXO adsorption on
citrate-coated apatite nanocrystals [24] and on BMNPs [18].
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Soluble Ff35 show a negative effect on HepG2 cell growth in a time and concentration-dependent
manner (Figure 4A). The IC50 values derived from the growth inhibition curves were of 6.23 ± 0.39,
1.37 ± 0.004, and 0.45 ± 0.10 µM for 24, 48, and 72 h, respectively. Lactate dehydrogenase (LDH)
activity in the culture medium was not detected after any of the treatments up to 10 µM of Ff35 (data
not shown), so the decrease in cell proliferation observed after the treatment with soluble Ff35 could
not be attributed to any acute cytotoxicity produced by plasma-membrane leakage. Ff35-BMNPs also
significantly decreased cell growth after 24 or 48 h of treatment. HepG2 cell proliferation was not
affected by the presence of BMNPs, which demonstrates the cytocompatibility of the BMNPs.
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respective controls.
Soluble Ff35 inhibits the activity of ChoKα1 (Figure 5A), with an IC50 value of 0.46 ± 0.079 µM.
In addition, choline uptake was also inhibited in the presence of soluble Ff35 in 55% and 75% at 0.5 µM
and 1 µM, respectively, after only 10 min of exposure. The effect was even more noticeable after 24 or
48 h of treatment, reaching inhibition levels of up to 68% and 88% at Ff35 0.5 µM and 1 µM, respectively,
after 48 h of treatment (Figure 5B). These results clearly indicate that soluble Ff35 inhibits strongly both
choline activity and absorption, and that the action of this compound in both processes is associated
with a decrease in cell proliferation.
Interestingly, the treatment with Ff35-BMNPs for 10 min did not produce significant changes in
the incorporation of choline into the cells compared with cells treated with BMNPs (Figure 5B) or in
control cells (Figure 5B). After 24–48 h of treatment, only a significant inhibition of choline uptake was
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observed at a concentration of Ff35 1 µM and BMNPs 300 µg mL−1. Nevertheless, this inhibition was
much lower than that observed with soluble Ff35 at the same concentration. The results indicate that
the functionalization of BMNPs with Ff35 strongly reduces the inhibitory effect of Ff35 on choline
uptake. To avoid completely the action of Ff35 on choline uptake, it would be necessary to control the
concentration of Ff35 as well as the time of treatment. It is likely that after a long treatment there may
be some release of the compound from the BMNPs that were not endocitated. This released Ff35 may
be responsible for the slight inhibition observed during treatment with Ff35-BMNPs (Ff35-BMNPs
1 µM and BMNPs 300 µg mL−1). However, the amount of compound released from Ff35-BMNPs
(Ff35-BMNPs 0.5 µM and BMNPs 150 µg mL−1) was not sufficient to inhibit choline uptake.
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Figure 5. (A) Effects of Ff35 on ChoKα1 activity assayed in purified ChoKα1 exposed to different Ff35
concentrations. The results are expressed as percentage of enzymatic inhibition. (B) Choline uptake
assay in HepG2 cells. Choline uptake was determined in cells treated for 10 min, 24 h, and 48 h soluble
Ff35 or Ff35-BMNPs. Results are normalized to their respective control. These experiments were
performed three times in triplicates. * p < 0.05, ** p < 0.001 compared to their respective controls.
However, despite the fact that Ff35-BMNPs had little effect on the uptake of choline, it produced a
marked decrease in cell proliferation, as mentioned above, similar to that observed in cells treated
with soluble Ff35 at the same concentration (Figure 4B). This is very important because, by coupling
Ff35 to the BMNPs, the antiproliferative effect of the compound is maintained as if Ff35 was soluble,
whereas any secondary effects associated to the inhibition of choline uptake induced by soluble Ff35
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are avoided or reduced. This new property improves the potential clinical use of Ff35 that would be
otherwise impeded.
TEM was used to visualize the internalization of BMNPs or Ff35-BMNPs (concentration of Ff35 was
1 µM and BMNPs was 300 µg mL−1), and to determine the possible morphological changes caused by
Ff35-BMNPs exposure. Ultrastructural analysis by TEM showed that BMNPs were internalized in the
cells by endocytosis (Figure 6). Control cells (Figure 6A,B) showed mitochondria having a dense matrix
as well as many cisternae of rough endoplasmic reticulum (ER) well structured, indicating absence of
cell damage. No ultrastructural cell damage was observed following BMNPs internalization until 24 h
incubation (Figure 6C,D), confirming the cell biocompatibility of these nanoparticles at a concentration
of 300 µg mL−1. Both the BMNPs (Figure 6C,D) and Ff35-BMNPs (Figure 6E,F) were internalized via
endocytosis and sorted into endosomes. As it can be seen, cells treated with Ff35-BMNPs showed
ultrastructural alteration, such as a notable dilatation of perinuclear space increasing separation of
two nuclear membranes, loss of mitochondrial density, and an abnormal shape. In general, the cells
exposed to the BMNPs showed a similar appearance to control cells, with not significant structural
alterations. These experiments confirm the cell damage following upon Ff35-BMNPs observed above,
and explain why, while soluble Ff35 inhibits choline uptake, Ff35-BMNPs do not. While soluble Ff35
requires choline transporter to enter the cell, Ff35-BMNPs enter the cells by endocytosis, and thus,
via a method that does not depend on choline transporters. Again, these results open the possibility
for a clinical use of ChoKα1 inhibitors by making their uptake by the cells independent of choline
transporters. Moreover, the experiments of the present study provide a protocol that allows us to
disentangle whether the cytotoxic activity of a ChoKα1 inhibitor such a Ff35 is due to the selective
inhibition of the enzyme, or on the contrary, due to the nonselective inhibition of the choline uptake
by the cell as an undesirable secondary effect. This protocol could be standardized and extended to
other molecules.
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We consider now the effect of hyperthermia and the combination hyperthermia-Ff35 on cell
proliferation. In all cases, the HepG2 cells were subjected to the magnetic field for periods of 1, 2, and
3 h. We assume that, according to generally accepted results, tumor cells are more sensitive than healthy
ones to a temperature increase [26], and, although 43 ◦C is widely accepted as a common threshold
for apoptosis of various cancer cells, many reports indicate that different thermal sensitivities exist
among different cell lines [27]. Hence, preliminary experiments aimed at setting the optimal conditions
of hyperthermia in HepG2 with the used BMNPs either bare or functionalized with Ff35. Figure 7
shows the effect of hyperthermia on the viability the cells, in comparison with cells not subjected
to the magnetic field. Hyperthermia reinforced cytotoxicity on both cells treated with BMNPs and,
much more so, on cells treated with Ff35-BMNPs. As it can be observed, after 2 h (and also 3 h) of
hyperthermia regime there was a significant decrease in viability (73% after 2 h and 79% after 3 h) of
cells maintained in the presence of BMNPs and AC field, revealing the cytotoxic effect of hyperthermia.
However, there were not significant differences between these two different times. On other hand,
significant differences in viability were found when the cells were treated with Ff35-BMNPs, with
and without field. It is shown in Figure 7 that the viability of cells treated with Ff35-BMNPs without
hyperthermia reached 67%, these values being lower in those cells treated with Ff35-BMNPs with
hyperthermia (54.8% for 1 h, 49.7% for 2 h, and 44.5% for 3 h). Since BMNPs are cytocompatible, these
results show that the temperature rise induced by them upon application of an alternating magnetic
field was responsible for the reduction in cell viability. However, such reduction was more evident and
faster upon the combination of drug release and hyperthermia. It is proposed that hyperthermia may
not only increase the local temperature, but also trigger the release of Ff35 from the BMNPs in the cells,
as already demonstrated to occur for other compounds [28].
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4. Conclusions
In summary, this study shows that the coupling of the ChoKα1 inhibitor Ff35 to BMNPs offers
great advantages. On one hand, since the nanocarrier is a magnetic nanoparticle, it opens the possibility
of a magnetic guidance to the target site through the application of a continuous magnetic field. Also,
it offers the possibility of also using the nanocarrier as a hyperthermia agent, thus combining the
cytotoxic effect of the molecule with the cytotoxic effect induced by hyperthermia and the triggering
of drug release from the BMNPs that hyperthermia induces. Finally, and no less important, it offers
the potential of Ff35 entering the cell independently of the choline transporters. This is crucial, as the
coupling of Ff35-BMNPs allows the compound to exert a cytotoxic activity comparable to that of the
soluble compound while avoiding the secondary effect linked to the inhibition of choline uptake. Also,
it provides a protocol that could be extensible to other molecules to disentangle the cytotoxic effect of
the drug in terms on enzyme inhibition and/or inhibition of choline uptake. Therefore, the novel design
of the nanoassemblies of Ff35-BMNPs showed in this study and the demonstration of the activity of
such a compound without interfering in the choline uptake are crucial results, as they would allow the
potential use of these ChoKα1 inhibitors as antitumoral drugs that would otherwise be compromised.
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